Drug Discovery
Antengene's ATG-022 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers
Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases o...
May 24, 2023 | News
HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics
HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhib...
May 19, 2023 | News
Fujitsu launches "Biodrug Design Accelerator" platform to accelerate peptide drug discovery research
Fujitsu today announced the commercial debut of its "Biodrug Design Accelerator," a platform to manage research processes for peptide (1) drug discovery, w...
May 18, 2023 | News
Antengene Clears U.S. IND for Phase I Trial of ATG-031 Antibody
- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncolog...
May 18, 2023 | News
Antengene Announces NDA Submission for XPOVIO® in Indonesia
"In just six months, we have submitted NDAs for XPOVIO® in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting...
May 17, 2023 | News
Innovent's IBI351 gets NMPA breakthrough designation for advanced colorectal carcinoma
This BTD for IBI351 was based on the pooled analysis of two ongoing clinical trials (NCT05005234, NCT05497336), which include 54 CRC pa...
May 15, 2023 | News
GenAssist's GEN6050 Base Editing Product Submits Pre-IND Application to FDA
Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA....
May 08, 2023 | News
ABM Initiates Phase I Clinical Trial of MEK Inhibitor for Solid Tumor, Doses First Patient
MEK (mitogen-activated protein kinase kinase), a key kinase of the MAPK pathway, is frequently activated in various cancers, including those with RAS mutat...
May 05, 2023 | News
Formosa Pharmaceuticals and AimMax Therapeutics Submit NDA to US FDA for APP13007 for Post-Operative Pain and Inflammation after Ocular Surgery.
This proprietary homogeneous nanosuspension has a solution-like appearance which offers great comfort to the eyes and enhanced drug penetration into ocular...
May 05, 2023 | News
Revolutionizing Drug Development: IQVIA's David Cameron on the Power of Innovative Trial Designs
Can you tell us about your role as Senior Director & Global Head of Novel Trial Design at IQVIA? The Novel Trial Design initiative at IQ...
May 09, 2023 | News
Toshiba's Heavy Ion Therapy System treats patients at Yonsei University Health System.
Toshiba Energy Systems & Solutions Corporation (hereinafter "Toshiba ESS") is pleased to announce today the commencement of treatment using a heavy ion...
April 30, 2023 | News
Bridgewest Perth Pharma to commercialize Sterile Injectable drugs under LumaCina business unit
The newly created business leverages the acclaimed team and production facility recently acquired by Bridgewest Group from Pfizer (Perth) Pty Ltd, a subsid...
April 26, 2023 | News
Cerner Enviza Collaborates with FDA to Develop Innovative AI Tools for Drug Safety and Real-World Evidence Studies
Cerner Enviza, an Oracle company, along with John Snow Labs, are now helping support the U.S. Food and Drug Administration’s drug safety Se...
April 25, 2023 | News
Most Read
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
